1. Home
  2. DAWN vs SEI Comparison

DAWN vs SEI Comparison

Compare DAWN & SEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DAWN
  • SEI
  • Stock Information
  • Founded
  • DAWN 2018
  • SEI 2014
  • Country
  • DAWN United States
  • SEI United States
  • Employees
  • DAWN N/A
  • SEI N/A
  • Industry
  • DAWN Biotechnology: Pharmaceutical Preparations
  • SEI
  • Sector
  • DAWN Health Care
  • SEI
  • Exchange
  • DAWN Nasdaq
  • SEI NYSE
  • Market Cap
  • DAWN 1.3B
  • SEI 1.1B
  • IPO Year
  • DAWN 2021
  • SEI 2017
  • Fundamental
  • Price
  • DAWN $12.15
  • SEI $26.77
  • Analyst Decision
  • DAWN Strong Buy
  • SEI Strong Buy
  • Analyst Count
  • DAWN 7
  • SEI 2
  • Target Price
  • DAWN $36.33
  • SEI $42.00
  • AVG Volume (30 Days)
  • DAWN 1.1M
  • SEI 1.1M
  • Earning Date
  • DAWN 02-24-2025
  • SEI 02-20-2025
  • Dividend Yield
  • DAWN N/A
  • SEI 1.77%
  • EPS Growth
  • DAWN N/A
  • SEI N/A
  • EPS
  • DAWN N/A
  • SEI 0.43
  • Revenue
  • DAWN $101,953,000.00
  • SEI $280,141,000.00
  • Revenue This Year
  • DAWN N/A
  • SEI $8.21
  • Revenue Next Year
  • DAWN $34.82
  • SEI $62.66
  • P/E Ratio
  • DAWN N/A
  • SEI $62.09
  • Revenue Growth
  • DAWN N/A
  • SEI N/A
  • 52 Week Low
  • DAWN $11.13
  • SEI $7.20
  • 52 Week High
  • DAWN $18.07
  • SEI $36.52
  • Technical
  • Relative Strength Index (RSI)
  • DAWN 44.59
  • SEI N/A
  • Support Level
  • DAWN $11.93
  • SEI N/A
  • Resistance Level
  • DAWN $13.53
  • SEI N/A
  • Average True Range (ATR)
  • DAWN 0.56
  • SEI 0.00
  • MACD
  • DAWN 0.03
  • SEI 0.00
  • Stochastic Oscillator
  • DAWN 35.21
  • SEI 0.00

About DAWN Day One Biopharmaceuticals Inc.

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.

About SEI SOLARIS ENERGY INFRASTRUCTURE INC

Solaris Energy Infrastructure Inc provides services in the oil and gas industry. Its solutions are Solaris software suite, Fluid management system, Automated control systems, Field services, Last mile management, Wet sand solutions, Power Solutions, and Integrated wellsite solution.

Share on Social Networks: